Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Crizotinib

Crizotinib: A Targeted Therapy for Non-Small Cell Lung Cancer and Beyond

Introduction

Crizotinib, an orally administered tyrosine kinase inhibitor (TKI), has revolutionized the treatment of certain cancers, particularly non-small cell lung cancer (NSCLC). Approved by the FDA in 2011 for the treatment of NSCLC with anaplastic lymphoma kinase (ALK) rearrangements, crizotinib has since been recognized for its activity against additional molecular targets, including c-MET and ROS1, making it a versatile agent in oncological therapies. 

Overview and Historical Context

Crizotinib was developed by Pfizer and was the first ALK inhibitor to gain FDA approval. The identification of ALK rearrangements in NSCLC in the early 2000s led to the development of crizotinib as a targeted therapy. Its approval marked a significant shift in the treatment paradigm for NSCLC, which had traditionally been treated with chemotherapy. Over time, crizotinib's use has expanded to other cancer types, making it a cornerstone in targeted cancer therapy.

Mechanism of Action

Crizotinib exerts its therapeutic effects through the inhibition of multiple tyrosine kinases, which play critical roles in the development and progression of various cancers.

  • ALK Inhibition: The primary mechanism of action of crizotinib is the inhibition of ALK, a receptor tyrosine kinase that is often aberrantly activated in cancers due to genetic rearrangements. In NSCLC, ALK gene rearrangements lead to the formation of fusion proteins, such as EML4-ALK, which drive tumor growth. Crizotinib binds to the ATP-binding site of ALK, preventing its activation and downstream signaling, thus inhibiting tumor cell proliferation and inducing apoptosis.

  • c-MET Inhibition: Crizotinib also targets c-MET, a receptor tyrosine kinase involved in cell survival, proliferation, and migration. Overactivation of c-MET has been implicated in the progression of several cancers, including NSCLC. By inhibiting c-MET, crizotinib can further reduce tumor growth and metastasis.

  • ROS1 Inhibition: ROS1 is another receptor tyrosine kinase involved in NSCLC and other cancers. Crizotinib inhibits ROS1 in a manner similar to ALK, blocking its oncogenic signaling pathway.

Pharmacokinetics and Pharmacodynamics

  • Absorption: Crizotinib is well absorbed after oral administration, with peak plasma concentrations occurring within 4-6 hours.

  • Bioavailability: Approximately 43%, with a food effect that increases bioavailability when taken with meals.

  • Distribution: Crizotinib is widely distributed throughout the body, including the lungs, liver, and brain, and it crosses the blood-brain barrier.

  • Metabolism: The drug is extensively metabolized in the liver, primarily by CYP3A4.

  • Half-life: The elimination half-life of crizotinib is approximately 42 hours, allowing for twice-daily dosing.

  • Excretion: It is primarily excreted in the feces, with a smaller amount eliminated in the urine.

Therapeutic Uses

  1. Non-Small Cell Lung Cancer (NSCLC)

    • ALK-positive NSCLC: Crizotinib is most commonly used in the treatment of advanced or metastatic NSCLC with ALK gene rearrangements. The approval for this indication was based on clinical trials showing significant improvements in progression-free survival (PFS) compared to traditional chemotherapy.

    • ROS1-positive NSCLC: Crizotinib is also effective in treating NSCLC with ROS1 gene rearrangements. Though less common than ALK rearrangements, ROS1 alterations are present in a subset of NSCLC patients and can be targeted with crizotinib.

  2. C-MET-Driven Cancers

    • Crizotinib is being studied in cancers driven by c-MET overexpression, including certain types of gastric cancer, renal cell carcinoma, and hepatocellular carcinoma.

  3. Other Cancer Types

    • Crizotinib is being investigated in clinical trials for cancers such as inflammatory myofibroblastic tumors (IMTs) and other solid tumors that may harbor ALK, ROS1, or c-MET alterations.

Dosing and Administration

Crizotinib is administered orally, typically at a dose of 250 mg twice daily. The dosage may be adjusted based on individual tolerance and the occurrence of side effects.

Side Effects and Toxicity

While crizotinib has shown efficacy in various cancers, it is associated with a range of side effects. The severity of side effects can vary depending on the patient’s overall health, concurrent therapies, and response to the drug.

  1. Common Side Effects

    • Gastrointestinal (GI) Disturbances: Nausea, vomiting, diarrhea, and constipation are frequently reported. These can often be managed with supportive care.

    • Visual Disturbances: Blurred vision and other visual disturbances have been reported in patients taking crizotinib. These symptoms typically resolve upon discontinuation of the drug.

    • Fatigue: Fatigue and malaise are common, affecting a significant proportion of patients.

    • Liver Toxicity: Elevated liver enzymes (AST, ALT) and hepatotoxicity are significant concerns. Regular liver function tests are essential during treatment.

    • Edema: Peripheral edema, particularly in the lower extremities, is frequently observed.

  2. Serious Side Effects

    • Interstitial Lung Disease (ILD): A potentially life-threatening condition characterized by inflammation and scarring of lung tissue. Patients should be monitored for respiratory symptoms, and the drug may need to be discontinued in the event of ILD.

    • QT Prolongation: Crizotinib may prolong the QT interval, potentially leading to arrhythmias. Baseline and periodic monitoring of the ECG is recommended.

    • Neutropenia and Thrombocytopenia: Decreased white blood cell and platelet counts can occur, increasing the risk of infections and bleeding.

Resistance Mechanisms

While crizotinib has been a game-changer in the treatment of ALK-positive NSCLC, resistance to the drug can develop over time. Resistance mechanisms include:

  1. Secondary Mutations in ALK

    • Mutations in the ALK kinase domain, such as the L1196M and G1202R mutations, can reduce the binding affinity of crizotinib, leading to treatment failure.

  2. Activation of Bypass Pathways

    • Upregulation of alternative signaling pathways, such as EGFR or HER2, can contribute to resistance.

  3. ROS1 and C-MET Alterations

    • Similar to ALK, mutations in ROS1 and c-MET can lead to primary or secondary resistance to crizotinib.

Management of Resistance

In cases of resistance, patients may be switched to second-line therapies such as:

  • Alectinib (for ALK-positive NSCLC)

  • Lorlatinib (for ALK-positive NSCLC)

  • Ceritinib (for ALK-positive NSCLC)

  • Entrectinib (for ROS1-positive NSCLC)

Monitoring and Supportive Care

Regular monitoring is critical to ensure the efficacy and safety of crizotinib therapy. Recommended monitoring includes:

  • Liver function tests to assess for hepatotoxicity

  • Electrocardiograms (ECG) to detect QT prolongation

  • Complete blood counts (CBC) to monitor for neutropenia and thrombocytopenia

  • Eye exams for visual disturbances

  • Pulmonary function tests (PFTs) to monitor for ILD

Conclusion

Crizotinib has established itself as an important therapy for ALK-positive and ROS1-positive non-small cell lung cancer, offering a targeted approach with improved outcomes compared to traditional chemotherapy. Its role is expanding to other cancers driven by molecular alterations such as c-MET, highlighting the potential for precision medicine in oncology. While resistance and side effects remain challenges, ongoing research into second-line therapies and combination regimens offers hope for continued success in cancer treatment. Crizotinib exemplifies the transformative potential of molecularly targeted therapies in the fight against cancer.

References

  • Shaw AT, et al. Crizotinib in ALK-positive lung cancer. N Engl J Med. 2013;368:2385-2394.

  • Solca F, et al. Targeting MET in cancer: Progress and challenges. Nat Rev Drug Discov. 2013;12:144-157.

  • National Comprehensive Cancer Network (NCCN) Guidelines: Non-Small Cell Lung Cancer. Version 4.2021.

  • FDA-approved prescribing information for Crizotinib.